06/12/2024

The Next Potential Alzheimer’s Drug Clears a Big Hurdle

The drug has been manufactured by Eli Lilly

After many years of slow progress, drug companies searching for the next big treatment for Alzheimer's disease are finally starting to see the fruits of their labors.

A panel of brain and Alzheimer’s experts convened by the U.S. Food and Drug Administration (FDA) voted unanimously on June 10 that a new Alzheimer's drug developed by Eli Lilly, called donanemab, is effective and that the benefits of the medication outweigh its risks. The agency will now take the committee's advice under consideration as it decides whether to approve the drug.

The FDA postponed its original decision on donanemab, which was scheduled for late last year, because it wanted to see more safety data on the medication. After Lilly provided additional information from a late-stage trial, the agency convened its advisory committee in June to review that safety data, as well as some of the more unique aspects of the company’s latest study.

Please select this link to read the complete article from TIME.